Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 3204504, 7 pages
Clinical Study

The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment

1Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical University, Lodz, Poland
2Department of Gastroenterology, Medical University, Lodz, Poland

Correspondence should be addressed to Jan Chojnacki; lp.zdol.demu@ikcanjohc.naj

Received 1 February 2017; Accepted 26 March 2017; Published 29 May 2017

Academic Editor: Thomas Minor

Copyright © 2017 Cezary Chojnacki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Taking statins can cause increase in the level of aspartate and alanine aminotransferase. The aim of this study was to assess the usefulness of melatonin in counteracting the adverse hepatic events from statins. Methods. The research program included 60 patients (aged 47–65 years, 41 women and 19 men) with hyperlipidemia taking atorvastatin or rosuvastatin at a dose of 20–40 mg daily. The patients were randomly allocated in two groups. Group I () was recommended to take the same statin at a standardized daily dose of 20 mg together with melatonin at a dose of  mg. Group II () patients took statin with placebo at the same dose and time of the day. Follow-up laboratory tests (AST, ALT, GGT, and ALP) were evaluated after 2, 4, and 6 months of treatment. Results. In Group I the levels of all enzymes decreased after 6 months, particularly AST,  U/L versus  U/L (); ALT,  U/L versus  U/L (); and GGT,  U/L versus 59,6 U/L (). Conclusion. Melatonin exerts a hepatoprotective effect in patients taking statins.